经典型霍奇金淋巴瘤的生物学:对预后和新型疗法的启示
经典型霍奇金淋巴瘤现代联合模式治疗治愈率超过80%,但青少年和年轻成人中治疗相关毒性与长期并发症仍是持续挑战,复发或难治患者在高剂量化疗和干细胞移植时代结局仍不理想。本文综述霍奇金淋巴瘤病理生物学知识,重点介绍靶向肿瘤细胞异常表型、失调致癌通路和免疫逃逸的新型治疗策略与预后模型开发进展。
要点
- 现代联合模式治疗下经典型霍奇金淋巴瘤治愈率超过80%,但青少年和年轻成人治疗相关毒性与长期并发症仍是持续挑战。
- 复发或难治患者在高剂量化疗和干细胞移植时代结局仍不理想,亟需新型替代治疗。
- 维布妥昔单抗和免疫检查点抑制剂已在复发/难治患者中显示成功并获得美国食品药品监督管理局批准。
核心结论
- 经典型霍奇金淋巴瘤现代联合模式治疗治愈率超过80%,但治疗相关毒性和长期并发症仍是持续挑战。
- 复发或难治患者在高剂量化疗和干细胞移植时代结局仍不理想,亟需新型创新替代治疗。
- 靶向霍奇金淋巴瘤分子标志的新型治疗药物不断涌现,维布妥昔单抗和免疫检查点抑制剂已获美国食品药品监督管理局批准。
- 作者预期新型分子检测的可及性和临床应用将在该病治疗格局快速转变的时代发挥关键作用。
研究设计与样本
- 综述,回顾经典型霍奇金淋巴瘤病理生物学当前知识,重点介绍相关新型治疗策略和预后模型的开发。
主要发现
- 现代联合模式治疗下经典型霍奇金淋巴瘤治愈率超过80%。
- 青少年和年轻成人中治疗相关毒性和长期并发症仍是持续挑战。
- 复发或难治患者在高剂量化疗和干细胞移植时代结局仍不理想。
- 维布妥昔单抗和免疫检查点抑制剂在复发/难治患者中已显示巨大成功,导致美国食品药品监督管理局批准及在不同临床背景中测试这些药物的新试验。
关键数值与推荐
- 经典型霍奇金淋巴瘤现代联合模式治疗治愈率超过80%。
临床怎么用
- 维布妥昔单抗和免疫检查点抑制剂已在复发/难治患者中显示成功并获得美国食品药品监督管理局批准。
- 作者预期新型分子检测的可及性和临床应用将有助于该病治疗格局的快速转变。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hodgkin lymphoma is considered a prime example of treatment success, with cure rates exceeding 80% using modern combined modality therapies. However, especially in adolescents and young adults, treatment-related toxicity and long-term morbidity still represent persistent challenges. Moreover, outcomes in patients with relapsed or refractory disease remain unfavorable in the era of high-dose chemotherapy and stem-cell transplantation. Hence, there is a high demand for novel and innovative alternative treatment approaches. In recent years, many new therapeutic agents have emerged from preclinical and clinical studies that target molecular hallmarks of Hodgkin lymphoma, including the aberrant phenotype of the tumor cells, deregulated oncogenic pathways, and immune escape. The antibody-drug conjugate brentuximab vedotin and immune checkpoint inhibitors have already shown great success in patients with relapsed/refractory disease, leading to US Food and Drug Administration approval and new trials testing these agents in various clinical settings. The expanding knowledge and understanding of Hodgkin lymphoma biology and disease progression, as well as the development of robust tools for biomarker-driven risk stratification and therapeutic decision making, continue to be fundamentally important for the success of these and other novel agents. We anticipate that the availability and clinical implementation of novel molecular assays will be instrumental in an era of rapid shifts in the treatment landscape of this disease. Here, we review the current knowledge of Hodgkin lymphoma pathobiology, highlighting the related development of novel treatment strategies and prognostic models that hold the promise to continually challenge and change the current standard of care in classical Hodgkin lymphoma.
引用
- Mottok A, Steidl C. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood. 2018. PMID: 29500175. doi:10.1182/blood-2017-09-772632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。